Initial experience of three-minute freeze cycles using the second-generation cryoballoon ablation: acute and short-term procedural outcomes.
The second-generation cryoballoon (CB-A) (Arctic Front Advance, Cryocath, Medtronic, MN, USA) might significantly improve procedural outcome with respect to the first-generation balloon. These technological improvements might also question the current recommendation of the need a 4-min freeze to achieve durable pulmonary vein isolation (PVI). The main aim of the study was to analyze the procedural efficacy of a 3-min freeze-thaw cycles with the CB-A balloon in the terms of rates of acute PVI and 6-month outcome. Patients having undergone CB-A for PAF or early persistent AF, with 3-min freeze-thaw cycles were consecutively included in our analysis. Acute procedural success was measured in terms of the rate of PVI. Short-term follow-up was evaluated by the means of 24-h Holters and clinical examinations at regular intervals. Fifty-two consecutive patients (35 male (67 %); mean age, 59.8 ± 10.5) were included. Mean procedure and fluoroscopy times were 96 ± 15 and 13.2 ± 8.3 min, respectively. Mean time from groin puncture to catheter extraction was 60.4 ± 20 min. After a mean of 1.5 freeze cycles per vein of 3 min in duration, all 208 (100 %) PVs could be isolated with the CB-A. A total 192 (91 %) veins were isolated during the first freeze. At a mean of 5.7-month follow-up, 82 % of patients were free of AF. CB-A is effective in producing PVI by using 3-min-duration freeze cycles. After a mean of 1.5 freeze per vein, freedom from AF was achieved in 82 % of patients at 6-month follow-up.